TMBIM4 and Huntington disease: These S1R-mediated neuroprotective effects of pridopidine previously described in preclinical models of NDD, potentially drive the beneficial therapeutic effects of pridopidine at 45 mg bid observed in patients with HD (PRIDE-HD) [1, 18].